Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Lexaria Bioscience (LEXX) over the last 15 years, with Q4 2025 value amounting to $1.5 million.

  • Lexaria Bioscience's Total Liabilities rose 28210.76% to $1.5 million in Q4 2025 from the same period last year, while for Nov 2025 it was $1.5 million, marking a year-over-year increase of 28210.76%. This contributed to the annual value of $1.6 million for FY2025, which is 3008.33% up from last year.
  • Latest data reveals that Lexaria Bioscience reported Total Liabilities of $1.5 million as of Q4 2025, which was up 28210.76% from $1.6 million recorded in Q3 2025.
  • Lexaria Bioscience's Total Liabilities' 5-year high stood at $1.9 million during Q1 2025, with a 5-year trough of $194623.0 in Q1 2022.
  • Moreover, its 5-year median value for Total Liabilities was $281450.5 (2021), whereas its average is $644461.7.
  • Its Total Liabilities has fluctuated over the past 5 years, first plummeted by 7735.69% in 2024, then soared by 83867.48% in 2025.
  • Lexaria Bioscience's Total Liabilities (Quarter) stood at $277328.0 in 2021, then increased by 1.51% to $281520.0 in 2022, then decreased by 9.76% to $254040.0 in 2023, then soared by 57.34% to $399718.0 in 2024, then soared by 282.11% to $1.5 million in 2025.
  • Its Total Liabilities stands at $1.5 million for Q4 2025, versus $1.6 million for Q3 2025 and $1.6 million for Q2 2025.